Helius Medical Technologies, Inc. (NASDAQ:HSDT) Short Interest Update

Helius Medical Technologies, Inc. (NASDAQ:HSDT) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 19,100 shares, a drop of 65.6% from the February 13th total of 55,500 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average trading volume of 4,430,000 shares, the short-interest ratio is currently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Helius Medical Technologies stock. Virtu Financial LLC acquired a new stake in Helius Medical Technologies, Inc. (NASDAQ:HSDT) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 46,510 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 1.25% of Helius Medical Technologies at the end of the most recent reporting period. 18.63% of the stock is currently owned by hedge funds and other institutional investors.

Helius Medical Technologies Trading Down 0.5 %

Shares of HSDT traded down $0.00 during midday trading on Friday, reaching $0.41. The stock had a trading volume of 75,610 shares, compared to its average volume of 1,404,501. The firm has a 50 day simple moving average of $0.60 and a 200-day simple moving average of $0.62. Helius Medical Technologies has a one year low of $0.37 and a one year high of $7.19. The firm has a market cap of $1.52 million, a PE ratio of -0.07 and a beta of 1.62.

Helius Medical Technologies Company Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.